Furthermore, CD69+ Vδ1γδ T cells are described as functional Vδ1γδ T cell subsets in patients with HCC, and circulating CD69+ Vδ1γδ T cell is a promising candidate in immunotherapy of HCC (57). The gene discussed is CD69; the disease is hepatocellular carcinoma.